Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1988 2
1990 2
1991 1
1992 5
1993 8
1994 11
1995 14
1996 30
1997 11
1998 21
1999 13
2000 22
2001 23
2002 32
2003 40
2004 47
2005 57
2006 46
2007 47
2008 65
2009 88
2010 71
2011 91
2012 103
2013 105
2014 106
2015 119
2016 86
2017 75
2018 80
2019 86
2020 109
2021 77
2022 99
2023 85
2024 44

Text availability

Article attribute

Article type

Publication date

Search Results

1,726 results

Results by year

Filters applied: . Clear all
Page 1
Comparison of empagliflozin and glimepiride as add-on to metformin in patients with type 2 diabetes: a 104-week randomised, active-controlled, double-blind, phase 3 trial.
Ridderstråle M, Andersen KR, Zeller C, Kim G, Woerle HJ, Broedl UC; EMPA-REG H2H-SU trial investigators. Ridderstråle M, et al. Lancet Diabetes Endocrinol. 2014 Sep;2(9):691-700. doi: 10.1016/S2213-8587(14)70120-2. Epub 2014 Jun 16. Lancet Diabetes Endocrinol. 2014. PMID: 24948511 Clinical Trial.
Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in HbA1c with empagliflozin versus glimepiride was -0.11% (95% CI -0.19 to -0.02; p=0.0153 for superiority). Adverse events were reported …
Empagliflozin was non-inferior to glimepiride at both timepoints. At week 104, adjusted mean difference in change from baseline in Hb …
Glimepiride pharmacokinetics in overdose.
Mégarbane B, Abe E, Chevillard L. Mégarbane B, et al. Clin Toxicol (Phila). 2022 Nov;60(11):1284-1285. doi: 10.1080/15563650.2022.2112692. Epub 2022 Aug 18. Clin Toxicol (Phila). 2022. PMID: 35980254 No abstract available.
Long-term efficacy and safety comparison of liraglutide, glimepiride and placebo, all in combination with metformin in type 2 diabetes: 2-year results from the LEAD-2 study.
Nauck M, Frid A, Hermansen K, Thomsen AB, During M, Shah N, Tankova T, Mitha I, Matthews DR. Nauck M, et al. Diabetes Obes Metab. 2013 Mar;15(3):204-12. doi: 10.1111/dom.12012. Epub 2012 Oct 11. Diabetes Obes Metab. 2013. PMID: 22985213 Review.

HbA1c decrease with liraglutide was non-inferior versus 0.5% decrease with glimepiride. Liraglutide groups experienced significant weight loss (2.1, 3.0 and 2.9 kg with 0.6, 1.2 and 1.8 mg, respectively) compared to weight gain (0.7 kg) with glimepiride (p < 0.00

HbA1c decrease with liraglutide was non-inferior versus 0.5% decrease with glimepiride. Liraglutide groups experienced significant we …
Clinical review of glimepiride.
McCall AL. McCall AL. Expert Opin Pharmacother. 2001 Apr;2(4):699-713. doi: 10.1517/14656566.2.4.699. Expert Opin Pharmacother. 2001. PMID: 11336617 Review.
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment of Type 2 diabetes mellitus (DM). Glimepiride therapy ameliorates the relative insulin secretory deficit found in most patients with …
This article reviews the pharmacological and clinical aspects of glimepiride, the latest second-generation sulfonylurea for treatment …
Pioglitazone hydrochloride/glimepiride.
Blake EW. Blake EW. Drugs Today (Barc). 2007 Jul;43(7):487-97. doi: 10.1358/dot.2007.43.7.1073850. Drugs Today (Barc). 2007. PMID: 17728849 Review.
Glimepiride stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. ...Guidelines are in place to limit patient selection for the use of pioglitazone based on cardiac risk factors. In general, pioglitazone and glimepir
Glimepiride stimulates insulin secretion from the pancreas with a decreased risk of hypoglycemia compared to glyburide. ...Guidelines
Clinical profile of glimepiride.
Draeger E. Draeger E. Diabetes Res Clin Pract. 1995 Aug;28 Suppl:S139-46. doi: 10.1016/0168-8227(95)01072-l. Diabetes Res Clin Pract. 1995. PMID: 8529506 Review.
In patients, glimepiride had a more rapid onset of action than glibenclamide, with a long duration of action. Glimepiride achieved metabolic control with the lowest dose (1-8 mg daily) of all the sulphonylureas. ...
In patients, glimepiride had a more rapid onset of action than glibenclamide, with a long duration of action. Glimepiride achi …
Effects of dapagliflozin compared with glimepiride on body composition in Asian patients with type 2 diabetes inadequately controlled with metformin: The BEYOND study.
Park HK, Kim KA, Min KW, Sohn TS, Jeong IK, Ahn CW, Kim NH, Park IB, Cho HC, Chung CH, Choi SH, Park KS, Yang SO, Lee KW. Park HK, et al. Diabetes Obes Metab. 2023 Sep;25(9):2743-2755. doi: 10.1111/dom.15164. Epub 2023 Jun 20. Diabetes Obes Metab. 2023. PMID: 37337747 Clinical Trial.
RESULTS: Of 124 enrolled patients from 14 centres, 121 received study treatment (dapagliflozin: 60; glimepiride: 61) and 106 (85.5%) completed the study. Over 52 weeks, the dapagliflozin group showed the following differences versus the glimepiride group: -2.59 kg B …
RESULTS: Of 124 enrolled patients from 14 centres, 121 received study treatment (dapagliflozin: 60; glimepiride: 61) and 106 (85.5%) …
Regardless of the degree of glycaemic control, linagliptin has lower hypoglycaemia risk than all doses of glimepiride, at all time points, over the course of a 2-year trial.
Gallwitz B, Rosenstock J, Patel S, von Eynatten M, Hehnke U, Mehlburger L, Dugi KA, Woerle HJ. Gallwitz B, et al. Diabetes Obes Metab. 2015 Mar;17(3):276-84. doi: 10.1111/dom.12419. Epub 2015 Jan 9. Diabetes Obes Metab. 2015. PMID: 25425502 Clinical Trial.
Patients randomized to glimepiride started on 1 mg and after 4 weeks were allowed to be individually uptitrated stepwise to glimepiride 4 mg if a fasting plasma glucose concentration 6.1 mmol/l was not achieved. ...In all 4-week intervals across the 2-year study, th …
Patients randomized to glimepiride started on 1 mg and after 4 weeks were allowed to be individually uptitrated stepwise to glimep
Glimepiride. A review of its use in the management of type 2 diabetes mellitus.
Langtry HD, Balfour JA. Langtry HD, et al. Drugs. 1998 Apr;55(4):563-84. doi: 10.2165/00003495-199855040-00007. Drugs. 1998. PMID: 9561345 Review.
Glimepiride was similar in efficacy to glibenclamide and glipizide in 1-year studies. However, glimepiride appears to reduce blood glucose more rapidly than glipizide over the first few weeks of treatment. ...
Glimepiride was similar in efficacy to glibenclamide and glipizide in 1-year studies. However, glimepiride appears to reduce b
The role of glimepiride in the treatment of type 2 diabetes mellitus.
Briscoe VJ, Griffith ML, Davis SN. Briscoe VJ, et al. Expert Opin Drug Metab Toxicol. 2010 Feb;6(2):225-35. doi: 10.1517/17425250903512955. Expert Opin Drug Metab Toxicol. 2010. PMID: 20055691 Review.
WHAT THE READER WILL GAIN: Pharmacology of glimepiride, data regarding clinical efficacy, key comparisons to other agents and emerging concepts related to glimepiride are discussed. TAKE HOME MESSAGE: Therapy with glimepiride improves the relative insulin sec …
WHAT THE READER WILL GAIN: Pharmacology of glimepiride, data regarding clinical efficacy, key comparisons to other agents and emergin …
1,726 results